Barclays raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $9 from $4 and keeps an Overweight rating on the shares. The firm expects meaningful indication expansion and margin improvements to drive longer-term upside in the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Largest borrow rate increases among liquid names
- Iovance Biotherapeutics price target raised to $1.50 from $1 at Goldman Sachs
- Iovance Biotherapeutics Reports Strong Q3 2025 Growth
- Iovance Biotherapeutics Reports Positive Earnings Amid Growth
- Midday Fly By: Qualcomm reports Q4 beat, Schwab acquires Forge